

What is Optimal Medical Therapy

Neal S. Kleiman MD Houston Methodist DeBakey Heart and Vascular Center Houston, TX, USA





I am an interventional cardiologist

Stable CAD: PCI vs. Medical Management Pre-COURAGE



Meta-analysis of 11 randomized trials; N = 2,950



Dual Goals for Management of Stable Ischemic Heart Disease (SIHD)



Prevent MI and Death (Disease Modification)

Improve "Quantity of Life"

Reduce Ischemia & Relieve Anginal Symptoms

Improve "Quality of Life"

Boden WE. Medical management of chronic coronary disease. Am J Cardiol. 2008;101:69D-74D. Gibbons RJ et al. Circulation. 2003;107:149-158. http://acc.org/qualityandscience/clinical/guidelines/stable/stable_clean.pdf.

Optimal ≠ Maximal





After Taking Medications





- CABG vs. "Medical Therapy" (minimal, by 2014 standards): 1970's-1980's
- PCI (BMS) vs. "Some" (but not diseasemodifying) Medical Therapy: 1990-2000
- PCI + "Optimal" Medical Therapy (OMT) vs.
 OMT alone: 2000-Present



RITA-2, 1018 patients (504 PTCA, 514 medical management)



No Difference in Outcome over Median of 7 Years

(Henderson, et al. JACC 2003;42:1161)

BARI 2D Study: Medical Therapy Versus Revascularization



Primary Outcome (All-Cause Death)



BARI 2D Study Group. N Engl J Med. 2009;360:2503-2512.

Survival (%)



Gated SPECT Results:



Post MI: Total PDS > 20%; IPDS > 10%

	Strategy 1 Medical Therapy (N=83)	Strategy 2 Revascularization (N=86)	p Value
Total PDS (Δ change)	-16.2 ± 10	-17.8±12	0.36
Ischemic PDS (Δ change) Scar PDS (Δ change)	-15.0±9	-16.2±9	0.44
	-1.2±8	-1.6±7	0.73
/o patients <u>></u> 9% decrease			
Total PDS	75	79	0.50
Ischemic PDS	80	81	0.76
LVEF (Δ change)	4.7±7	4.6±8	0.93

Mahmarian J. J. Am Coll Cardiol.2006;48:2458



ESTABLISHED IN 1812

APRIL 12, 2007

VOL. 356 NO. 15

Optimal Medical Therapy with or without PCI for Stable Coronary Disease

2287 patients

"Optimal Medical Therapy" At 5 yrs: 70% had LDL <100 mg/dl; median LDL = 71 mg/dl at 5 yrs 65% and 94% had SBP and DBP < 130/85 mmHg, respectively 45% of patients with diabetes had Hb A1c <7% High adherence to diet, exercise, smoking cessation, and meds

97% BMS; 3% DES; all patients suitable for PCI; intermediate event rate

What Was Achieved with Optimal Medical Therapy (OMT) in COURAGE...

Primary Endpoint: Survival Free of Death or MI





 Intensive, Guideline-driven Medical Therapy & Lifestyle Intervention In Both Groups



COURAGE: Freedom From Angina





Boden et al. N Engl J Med 2007; 356: 1503-1516.

Pharmacologic Therapy in SIHD: 2000



Disease-Modifying Therapy

- Aspirin
- Statins
- ACE inhibitors and/or ARBs
- Beta-blockers Post-MI

Symptomatic Treatment for Angina/Ischemia Control

- Beta-blockers w/o MI
- Calcium antagonists
- Nitrates

Boden WE et al. N Engl J Med. 2007; 356:1503-1516.

Pharmacologic Therapy in SIHD: 2014



Disease-Modifying Therapy

- Aspirin
- Thienopyridines
- ? Vorapaxar
- Statins (Higher dose)
- ACE inhibitors and/or ARBs
- Beta-blocker Post-MI
- Aldosterone Inhibitors
- ? Fibrates and Niacin

Symptomatic Treatment for Angina/Ischemia Control

- Beta-blockers w/o MI
- Calcium antagonists
- Nitrates
- Ranolazine
 - Ivabradine (in Europe)



Non-Stent Thrombosis Myocardial Infarction





COURAGE Treatment Goals



- Aspirin Use
- Blood pressure < 130/85 (<80 if diabetic)</p>
- LDL-C < 85 mg/dL (lowered in 2004)</p>
- HDL-C <u>></u> 40 mg/dL
- TG < 150 mg/dL</p>
- Fasting glucose < 126 mg/dL</p>
- Non-smoking
- BMI <25 kg/m²
- Exercise <u>></u> 4 days/wk

COURAGE Treatment Goals



- Aspirin Use
- Blood pressure < 130/85 (<80 if diabetic)</p>
- LDL-C < 85 mg/dL (lowered to ≤70 in 2004)</p>
- HDL-C ≥ 40 mg/dL
- TG < 150 mg/dL</p>
- Fasting glucose < 126 mg/dL</p>
- Non-smoking
- BMI <25 kg/m²
- Exercise <u>></u> 4 days/wk

COURAGE: Trends in Lifestyle Modification and Medication Use







J Am Coll Cardiol. 2010;55(13):1348-1358

COURAGE: Trends in Lifestyle Modification and Medication Use





J Am Coll Cardiol. 2010;55(13):1348-1358. doi:10.1016/j.jacc.2009.10.062



Optimal medical therapy is really the treatment that the patient will let you give him/her.



- Patients met with a nurse case manager at baseline, 1, 2, 3, 6 months, then every 6 months thereafter.
- How does this procedure play out in the real world?
 - Systematic vs fragmented approach to health care

REGARDS Study



- Cohort study of 30,239 individuals in the Southeast US recruited 2003-7 with longitudinal follow-up
- 42% African American; 55% female
- 4,245 reported history of CAD (MI, PCI, CABG)
 - Mean age = 69+/- 9 years
 - 1/3 African American
 - 1/3 Female

Percentage of Subjects Reaching Each Goal





Brown. JACC.2014;63:1626

Percentage Achieving Goals





Brown. JACC.2014;63:1626

Predictors of Achieving Goals for Aspirin, BP Control, and LDL Control



- Age
- Sex
- Region of Southeast US
- Urban vs Rural
- Income
- Education
- Kidney function
- Physical component score of SF-12

OMT in Patients Receiving OMT: Before and After COURAGE



- ACC CathPCI Registry Database 2005-9
- 467,211 Patients at 1,013 hospitals
- Analysis based on prescriptions filled; patients with contraindications were excluded



OMT = Aspirin or thienopyridine, β -blocker, statin, ACE/ARB if indicated

Borden: JAMA. 2011; 305: 1882.

OMT Before and After PCI



After PCI

Before PCI



Borden: JAMA. 2011;305:1882.

Major Points



- OMT is the winner with or without PCI
- The definition of OMT is fluid -- in a big way
- Administering and maintaining OMT requires a wellmaintained infrastructure
- PCI seems to be a focal point that allows patients entry into a world of more optimized medical therapy